Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.55 |
| ▸ | BRAF | P15056 | 5/20 | 0.55 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17465845 | 0.90 | EGFR (0.57) | EGFRBRAFABL1BCRMAP4K2 | |
| SCHEMBL17465846 | 0.81 | MAP4K2 (0.52) | EGFRBRAFMAP4K2TNK2MAP3K7 | |
| SCHEMBL17465844 | 0.79 | EGFR (0.54) | EGFRBRAFABL1BCRMAP4K2 | |
| SCHEMBL17465847 | 0.78 | MAP3K7 (0.54) | EGFRBRAFABL1MAP4K2MAP3K7 | |
| SCHEMBL16065802 | 0.78 | TNK2 (0.58) | TNK2 | |
| SCHEMBL3139682 | 0.73 | MAP4K2 (0.78) | EGFRBRAFABL1MAP4K2TNK2 | |
| SCHEMBL17469527 | 0.72 | CCNK (0.46) | TNK2 | |
| SCHEMBL4869570 | 0.72 | MAPK14 (0.60) | EGFRBRAFABL1BCRMAP4K2 | |
| SCHEMBL3139822 | 0.71 | MAPT (0.53) | EGFRBRAFABL1MAP4K2TNK2 | |
| SCHEMBL13878785 | 0.71 | EGFR (0.67) | EGFRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885BRAF 353/4885ABL1 140/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885BRAF 353/4885ABL1 140/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | EGFR 662/4885BRAF 353/4885ABL1 140/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | EGFR 662/4885BRAF 353/4885ABL1 140/4885 |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885BRAF 353/4885ABL1 140/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | EGFR 662/4885BRAF 353/4885ABL1 140/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885BRAF 353/4885ABL1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.